BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 33068050)

  • 1. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterisation of six human biliary tract cancer cell lines.
    Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
    Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
    Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
    Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A; Wittekind C
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.
    Samadder NJ; Smith KR; Wong J; Hanson H; Boucher K; Burt RW; Charlton M; Byrne KR; Gallegos-Orozco JF; Koptiuch C; Curtin K
    Dig Dis Sci; 2016 Dec; 61(12):3627-3632. PubMed ID: 27655103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
    Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
    Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
    Nagao M; Mizukoshi K; Nakayama S; Namikawa M; Hiramatsu Y; Maruno T; Nakanishi Y; Tsuruyama T; Fukuda A; Seno H
    Oncotarget; 2023 Mar; 14():276-279. PubMed ID: 36999984
    [No Abstract]   [Full Text] [Related]  

  • 12. Isolation, culture and characterization of biliary epithelial cells from different anatomical levels of the intrahepatic and extrahepatic biliary tree from a mouse.
    Katayanagi K; Kono N; Nakanuma Y
    Liver; 1998 Apr; 18(2):90-8. PubMed ID: 9588767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse Model for Cholangiocarcinoma from Peribiliary Glands.
    Nakagawa H; Suzuki N; Koike K
    Methods Mol Biol; 2019; 1905():237-245. PubMed ID: 30536105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
    J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Differences in Human Biliary Tissues and Corresponding In Vitro-Derived Organoids.
    Rimland CA; Tilson SG; Morell CM; Tomaz RA; Lu WY; Adams SE; Georgakopoulos N; Otaizo-Carrasquero F; Myers TG; Ferdinand JR; Gieseck RL; Sampaziotis F; Tysoe OC; Ross A; Kraiczy JM; Wesley B; Muraro D; Zilbauer M; Oniscu GC; Hannan NRF; Forbes SJ; Saeb-Parsy K; Wynn TA; Vallier L
    Hepatology; 2021 Jan; 73(1):247-267. PubMed ID: 32222998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.
    Nakagawa R; Hiep NC; Ouchi H; Sato Y; Harada K
    Med Mol Morphol; 2020 Mar; 53(1):42-49. PubMed ID: 31432248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
    Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
    Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.